Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/t-halidomide-emerging-role-in-cancer-medicine-61sJ9m0TRP
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2002 by Annual Reviews. All rights reserved
- Subject
- Review Articles
- ISSN
- 0066-4219
- eISSN
- 1545-326X
- DOI
- 10.1146/annurev.med.53.082901.104043
- pmid
- 11818493
- Publisher site
- See Article on Publisher Site
Abstract
▪ Abstract Thalidomide—removed from widespread clinical use by 1962 because of severe teratogenicity—has antiangiogenic and immunomodulatory effects, including the inhibition of tumor necrosis alpha factor. It has now returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was approved by the U.S. Food and Drug Administration in 1998, and more recently certain malignancies, including multiple myeloma. Although thalidomide's mechanism of action remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials have confirmed benefit in relapsed disease, and the role of thalidomide in treating newly diagnosed patients is currently under study. Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma. Activity has also been demonstrated in chronic graft-versus-host disease and in symptom relief as part of palliative care.
Journal
Annual Review of Medicine – Annual Reviews
Published: Feb 1, 2002